Table I.
Major characteristics of the trials included.
| Patients | ||||||||
|---|---|---|---|---|---|---|---|---|
| First author (year) | Interventions | Study duration (weeks) | N (% males) | Age (years) | Pain score at baseline (mm) | PGA at baseline (mm) | BASFI at baseline (mm) | (Refs.) |
| Balazcs (2016) | Etoricoxib 60/90 mg/d Naproxen 1,000 mg/d | 6 | 1015 (70.9) | 45.2 | 76.8 | NR | NR | (21) |
| Barkhuizen (2006) | Celecoxib 200/400 mg/d Naproxen 1,000 mg/d Placebo | 12 | 611 (73.8) | 44.6 | 71.9 | 66.6 | 52.1 | (24) |
| Dougados (1999) | Meloxicam 15/22.5 mg/d Placebo | 6 | 365 (78.7) | 42.0 | 71.0 | NR | NR | (26) |
| Dougados (2001) | Celecoxib 200 mg/d Placebo | 6 | 156 (70.5) | 39.0 | 70.0 | 44.5 | 44.5 | (25) |
| Fattahi (2018) | M2000 1,000 mg/d Naproxen 1,000 mg/d Placebo | 12 | 85 (70.6) | 30.5 | 61.5 | 62.8 | 44.3 | (27) |
| Huang (2014) | Celecoxib 200 mg/d Diclofenac 75 mg/d | 6 | 240 (85.8) | 29.3 | 63.4 | NR | NR | (18) |
| Sieper (2008) | Celecoxib 200/400 mg/d Diclofenac 150 mg/d | 12 | 458 (69.2) | 44.8 | 66.0 | 44.0 | 44.0 | (19) |
| van der Heijde (2005) | Etoricoxib 90/120 mg/d Naproxen 1,000 mg/d Placebo | 6 | 387 (77.8) | 43.6 | 77.6 | 55.1 | 55.1 | (20) |
| Walker (2016) | Celecoxib 200/400 mg/d Diclofenac 150 mg/d | 12 | 330 (72.4) | 43.8 | 65.5 | 65.4 | 47.3 | (22) |
PGA, patient's global assessment of disease activity; BASFI, Bath Ankylosing Spondylitis Functional Index; NR, not reported; M2000, beta-D-mannuronic acid.